New drug trial targets rare cancers, but halted for now
NCT ID NCT05337735
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This phase 2 trial is testing a drug called XmAb20717 in people with advanced rare cancers, including mesothelioma, lymphoma, and small cell lung cancer. The goal is to see if the drug can shrink tumors and is safe. The trial is currently suspended, so results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XmAb20717 (a drug given by IV)
What this could lead to
If it works, this could point toward a new treatment option for several rare cancers that are hard to treat.
What could go wrong
This is an early phase 2 trial, so it's still uncertain if the drug will work. The trial is currently suspended, which may indicate challenges. Side effects from the drug are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.